RESEARCH AND DEVELOPMENT AGREEMENT EIGHTH AMENDMENTResearch and Development • March 16th, 2015 • Omeros Corp • Pharmaceutical preparations
This is an amendment effective 21 March 2012 (this “Amendment”) of the Exclusive License and Sponsored Research Agreement dated 10 June 2004 as last amended
SECOND AMENDMENT TO PROJECT AGREEMENT (Detailing and Sales Operations Services)Project Agreement • March 16th, 2015 • Omeros Corp • Pharmaceutical preparations
This Second Amendment (the “Second Amendment”) dated August 19, 2014 (the “Effective Date”) is made by and between Ventiv Commercial Services, LLC, with an office at 500 Atrium Drive, Somerset, N.J. 08873 (“inVentiv”) and Omeros Corporation, with an office at 201 Elliott Avenue West, Seattle, WA 98119 (referred to herein as the “Client”). inVentiv and Client may each be referred to herein as a “Party” and, collectively, as the “Parties.”
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • March 16th, 2015 • Omeros Corp • Pharmaceutical preparations • Delaware
THIS COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of the 3rd day of October, 2014 (the “Effective Date”) by and among Omeros Corporation, a Washington corporation, having its principal offices at 201 Elliott Avenue West, Seattle, Washington 98119 (“Omeros”), and Hospira S.p.A., having its registered address at [†] (“Hospira [†]”) on behalf of its Affiliated corporation, Hospira Worldwide, Inc., having a principal place of business at 275 North Field Drive, Lake Forest, Illinois, 60045, (U.S.A.) (“Hospira US”). For purposes of this Agreement, Hospira [†] and Hospira US shall be referred to collectively as “Hospira”, unless the content requires otherwise. Each of Hospira and Omeros is referred to herein individually as a “Party” and together as the “Parties”.
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 16th, 2015 • Omeros Corp • Pharmaceutical preparations
THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 30, 2014, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “Lender” and collectively, the “Lenders”) and OMEROS CORPORATION, a Washington corporation (“Borrower”).
